Antipsychotic Drugs
Market Research Report: Information by Generation (First Generation, Second
Generation), Types of Antipsychotics (Atypical Antipsychotics, Miscellaneous
Antipsychotics Agents), Therapeutic Applications(Schizophrenia, Anxiety,
Bipolar Disorder) and Region (the Americas, Europe, Asia-Pacific, and the
Middle East & Africa) - Forecast till 2025
Psychosis is a collective
term used to cover are a group of disorders that are regarding the serious
distortion of behavior, thought, recognition of reality, and perception. Drugs
that are useful for treating psychosis are called antipsychotic drugs. A new
report on the global Antipsychotic
Drugs Market, published by Market Research Future
(MRFR), assays that this market can touch success at 4.3% CAGR between 2017 and
2022. In terms of money value, the market can be worth USD 18.5 Bn by the end
of the forecast period.
Assaying the market
structure, this report accounts the future growth potential of the market. It
characterizes the strategies of the topmost market players in the market and
supports the competitive developments like research & developments
(R&D), mergers & acquisitions, new product developments, and joint
ventures, in the market.
The most significant
market driving factor for the global antipsychotic drugs market growth is unmet
medical needs of an order of 35% and 50% of people with mental disorders.
Increasing the focus of governments and health care organizations on mental
health is also boosting the market. Other factors contributing to the global
antipsychotic drugs market growth include research & development research
& development (R&D) on many antipsychotic drugs. However, some factors
that can hinder the global antipsychotic drugs market growth include social
stigma faced by patients, poor drug development pipeline, and a strict
regulatory framework. The side effects of antipsychotic drugs range from
drowsiness, insomnia, vomiting to the high addiction rate. Hence, many patients
hesitate to use these drugs. The poor efficiency and efficacy of antipsychotic
drugs also hurt its market growth.
Market
Segmentation
The global antipsychotic
drugs market segmentation encompasses generations and therapeutic applications.
MRFR’s take on the market surveys various facets of the market in-depth.
The generations-based
segmentation of this market covers the first generation, second generation, and
third generation. Regarding therapeutic applications, the market has been
segmented into bipolar disorder, dementia, depression, schizophrenia, and
others.
Browse Complete Report : https://www.marketresearchfuture.com/reports/antipsychotic-drugs-market-2784
Regional
Segmentation
A geographical outlining
of the global antipsychotic drugs market covers the Americas (North America
& South America), Europe, Asia Pacific, and the Middle East & Africa
(MEA).
The Americas is the
largest regional market as North America alone holds the potential of being a
dominant market due to heavy investment in the R&D related to medicines and
drugs. Due to technological advancements and availability of advanced medical
facilities, North America is a bigger regional market segment than South
America. USA and Canada generate maximum market revenue in this region. Many
important key market players are based in the USA. Two most important market
driving factors in this region are excellent reimbursements scenario in the USA
and the rapid uptake of new drug molecules. Most of the crucial market players
are based in the USA.
Europe is the
second-largest regional market due to the high density of population and other
reasons being the same as in North America. The most powerful country-specific
markets in Europe are France, Germany, Italy, Spain, and the UK. An inspection
of the remaining countries in Europe featured in this report speculate the huge
contribution to market revenue from some other countries in this region.
During the forecast
period, the Asia Pacific region can be the fastest growing regional market high
density of population, improving healthcare facilities, and government efforts
to improve healthcare, especially in China and India. Other pivotal
country-specific markets in this region are Japan and South Korea. An
observation of the remaining countries in the Asia Pacific region featured in
this report calculates the huge addition to market revenue from some other
countries.
The MEA region holds the
lowest share in the global market due to poor medical facilities and lack of
skilled professionals.
Key
Players
Big players in the global
antipsychotic drugs market AstraZeneca (UK), Bristol-Myers Squibb (USA), Eli
Lilly and Company (USA), GlaxoSmithKline PLC (UK), Johnson & Johnson (USA),
and Pfizer Inc. (USA).
Latest
Industry News
·
ACADIA Pharmaceuticals Inc. has announced
its Phase 3 HARMONY study. This is going to be a double-blind,
placebo-controlled relapse prevention trial that would evaluate pimavanserin
for the treatment of dementia-related psychosis. 9 SEP 2019
No comments:
Post a Comment